The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Among older patients with diabetes, glucagon-like peptide 1 receptor agonists were associated with an increased risk for ...

In the late 2010s, Novo Nordisk shelved a weekly obesity treatment that targeted three hormones at once, though it caused ...

U.K. regulators issued guidance on Thursday, warning weight loss and diabetes medications may weaken the effectiveness of ...

A consensus statement from the Society for Perioperative Assessment and Quality Improvement recommends patients should ...

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

Being cut off in traffic, giving a presentation or missing a meal can all trigger a suite of physiological changes that allow ...

As of 2021–2022, approximately 74% of U.S. adults aged 20 and older were classified as overweight or obese, with 42.1% ...

The widespread adoption of GLP-1 (glucagon-like peptide-1) receptor agonist medications, such as Ozempic and Wegovy, is ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

The Mounjaro 'golden dose' has been explained after doctors issued an urgent warning over the potential deadly hack.